Summary of Partners Group Conference Call (January 14, 2026) Company Overview - **Company**: Partners Group (OTCPK: PGPH.F) - **Date**: January 14, 2026 - **Context**: Announcement of Assets Under Management (AUM) as of December 31, 2025 Key Points Industry and Market Environment - The investment environment in 2025 was characterized by macroeconomic uncertainty and geopolitical instability, yet Partners Group managed to grow its AUM by 21% overall [2][4] - The industry remains below peak levels, with a bifurcation between successful firms and those struggling [4] Financial Performance - **AUM Growth**: Increased by 21%, adding $30.2 billion in total new assets, exceeding the guidance of $26-$31 billion [2][26] - **Fundraising**: Achieved $26 billion in fundraising, marking the highest year for new client demand in the company's history, a 22% increase from the previous year [2][15] - **Investment Deployment**: Deployed $27 billion in 2025, a 26% increase year-over-year [3][11] - **Realizations**: Realizations were up 47%, primarily from pre-2022 vintages, with an average premium at exit [3][5] Investment Strategy - Partners Group positions itself as a leading provider of portfolio solutions in private markets, with bespoke solutions contributing 72% of inflows [3][4] - The company has a strong thematic pipeline, particularly in infrastructure, digitization, and energy transition platforms [11][12] - Notable investments include: - **Infinity Fincorp Solutions**: Customized secured loans in India, benefiting from economic growth and digitization [12] - **Life Cycle Power**: Mobile power generation solutions in the US, capitalizing on increased data center power demand [13] - **Royalties Business**: Investment in a royalty spec note for The Weeknd, diversifying cash flows across sectors [13] Performance Fees and Guidance - Performance fees for 2025 are expected to exceed 30% of revenue, with a pull-forward effect from transactions like PCI Pharma Services [8][9] - For 2026, performance fee expectations are set between 25%-40% of revenues, with a cautious outlook due to the pull-forward effect [9][29] - The company anticipates $26 billion to $32 billion in new assets for 2026, reflecting strong fundraising momentum [29] Evergreen Platform and Private Wealth - The Evergreen platform saw inflows of $9.4 billion, a 12% year-on-year increase, with 59% of total inflows coming from new funds [18][19] - Redemption levels increased to 11% in 2025, consistent with a maturing market, but are expected to be offset by NAV growth [20][21] Strategic Partnerships - The company is focused on building strategic relationships with large institutions and expanding its mandate offerings, particularly in Asia and the Middle East [29] - A partnership with Deutsche Bank aims to create a flagship private markets offering for over 20 million clients [24][25] Future Outlook - The company is well-positioned to navigate a complex environment in 2026, with a focus on expanding its diversified Evergreen platform and capturing new client segments [29][30] - Anticipated tail-downs for 2026 are estimated at $10-$13 billion, driven by close-ended traditional funds [30] Additional Insights - The company emphasizes the importance of customization in its offerings, particularly in response to the evolving needs of private wealth clients [19][20] - The performance of Evergreen funds is influenced by vintage share exposure, with newer funds showing strong returns [22][23] This summary encapsulates the key points discussed during the Partners Group conference call, highlighting the company's performance, strategic initiatives, and outlook for the future.

Omada Health FY Conference Summary Company Overview - **Company**: Omada Health (NasdaqGS:OMDA) - **Industry**: Digital Health and Chronic Disease Management - **Mission**: To bend the curve of disease and improve care for chronic disease patients, particularly those with obesity, diabetes, and other related conditions [3][4] Key Highlights Financial Performance - **Revenue**: $257 million for FY 2025, representing a **52% year-over-year growth** [6][26] - **Members Supported**: 886,000 active members [7][26] - **Adjusted Gross Margin**: Upper 60s% for LTM Q3 2025, improved from the 50s% in 2022 [26] - **Adjusted EBITDA Margin**: -2.4% for LTM Q3 2025, improved from nearly -70% in 2022, with the first positive adjusted EBITDA quarter of $2.4 million in Q3 2025 [27] Market Position and Strategy - **Target Market**: Over 20 million Americans covered by Omada's programs through 2,000+ customers, including self-insured employers and health plans [5][18] - **Expansion**: Initially focused on prediabetes and obesity, now expanded to diabetes, hypertension, and musculoskeletal (MSK) care [6][9] - **Growth Drivers**: - Multi-product offerings, including the new GLP-1 Care Track [21] - Customer-driven expansion based on demand for comprehensive care solutions [9][19] Product and Service Offerings - **Care Model**: Combines technology and personalized care to support patients between doctor visits [5][10] - **GLP-1 Care Track**: Launched to provide behavioral support alongside GLP-1 medications, addressing concerns about medication adherence and effectiveness [21][22] - **Engagement Metrics**: Over 55% of members remain engaged after 12 months, and 50% after two years [14][15] Clinical and Economic Outcomes - **Clinical Evidence**: 30 peer-reviewed publications demonstrating the effectiveness of Omada's programs [15][16] - **Economic Value**: Expected ROI of 3-6x in musculoskeletal care, with gross healthcare savings of $1,000-$1,500 per member [16][26] Future Outlook - **Investment Focus for 2026**: Emphasis on AI initiatives and enhancing prescribing capabilities to drive long-term growth and margin expansion [41][42] - **Market Trends**: Increased focus on chronic disease management from government and employers, with potential opportunities in Medicare Advantage [54][56] - **Customer Demand**: Growing interest in combining prescribing with behavioral management for chronic conditions [43][44] Additional Insights - **Customer Relationships**: Strong demand for multi-product solutions, with 75% of new clients opting for more than one condition [52] - **Regulatory Environment**: Positive dialogue with government regarding chronic disease management, indicating potential for future partnerships [54][56] - **Technological Integration**: Use of AI to enhance member experience and operational efficiency, with features like nutritional intelligence agents [38][39] This summary encapsulates the key points from Omada Health's FY conference, highlighting the company's growth, strategic direction, and the evolving landscape of chronic disease management.

Larimar Therapeutics (NasdaqGM:LRMR) FY Conference January 14, 2026 12:00 PM ET Company ParticipantsCarole Ben-Maimon - President and CEOConference Call ParticipantsHenry Jiang - AnalystHenry JiangToday, my name is Henry Jiang. I'm with the banking team here at JPMorgan, and it's my pleasure to introduce Larimar Therapeutics today. Presenting today will be Dr. Carole Ben-Maimon, President and CEO of Larimar. Just a quick note: we'll have time for Q&A after the presentation, so please wait until then for any ...

Summary of Legend Biotech Conference Call Company Overview - **Company**: Legend Biotech - **Industry**: Biotechnology, specifically focused on cell therapy - **Key Product**: Carvykti, a CAR-T therapy for multiple myeloma - **Market Position**: World's largest standalone cell therapy company, leading in CAR-T therapy for multiple myeloma [2][3] Core Points and Arguments Financial Performance - Carvykti generated approximately **$1.7 billion** in net trade sales over the last 12 months [3] - The company has a cash position of nearly **$1 billion** and has achieved positive operating profit for Carvykti in Q3 [4] - Legend anticipates achieving company-wide profitability in 2026, with Carvykti expected to generate over **$5 billion** in annual peak sales [5][8] Product Efficacy and Market Penetration - Carvykti has treated over **10,000 patients**, demonstrating a **97% manufacturing success rate** [6][8] - The therapy has shown a **median progression-free survival (PFS)** of nearly **35 months** in heavily pretreated patients [10] - In the CARTITUDE-4 trial, the median PFS has not yet been reached after nearly three years of follow-up [10][44] - Carvykti is the only CAR-T therapy to achieve a **five-year remission survival** in one-third of patients after a single infusion [9] Market Expansion and Strategy - The company is expanding its global presence, with **279 treatment sites** in **14 countries** [6] - A partnership with Johnson & Johnson (J&J) is aimed at maximizing Carvykti's potential, with a **50/50 cost-sharing and profit split** in the U.S. [8] - The company is focusing on community settings, where **70%** of relapsed and refractory multiple myeloma patients are treated [15] Clinical Trials and Future Directions - Ongoing trials (CARTITUDE-5 and CARTITUDE-6) are evaluating Carvykti in newly diagnosed patients, with the goal of addressing an additional **50,000 patients** annually [14] - The company is also exploring allogeneic therapies and in vivo CAR-T programs, with a focus on capital efficiency and rapid clinical proof of concept [21][23] Competitive Landscape - Despite competition in the multiple myeloma market, Legend emphasizes Carvykti's superior survival outcomes and unique one-time treatment benefits [30][37] - The current market penetration for BCMA-targeted therapies is low, with less than **10%** in fifth-line treatments and less than **5%** in second to fourth-line treatments, indicating significant growth potential [13][35] Additional Important Insights - The National Comprehensive Cancer Network (NCCN) has updated guidelines recommending Talvey as a bridging therapy to BCMA CAR-T therapy, which is expected to be adopted quickly [19] - The company has improved its manufacturing turnaround time to below **30 days**, supporting increased supply capacity [31] - The collaboration with J&J includes a **30/70** cost-sharing arrangement for the China market, where Legend leads [32] Conclusion Legend Biotech is positioned as a leader in the CAR-T therapy market for multiple myeloma, with strong financial performance, promising clinical outcomes, and a strategic focus on expanding its market presence and pipeline development. The company aims to leverage its successful R&D model to explore new therapeutic areas while maintaining profitability and enhancing patient outcomes.

Concentra Group Holdings Parent (NYSE:CON) FY Conference Summary Company Overview - **Company Name**: Concentra Group Holdings - **Industry**: Occupational Health Services - **Key Leadership**: CEO Keith Newton, CFO Matt DiCanio, SVP of Finance and Strategy Tanner Newton - **Public Trading**: Became publicly traded in July 2024 after a spin-off from Select Medical [2][22] Core Business Insights - **Market Position**: Largest occupational health services provider in the U.S., treating 1 out of every 4 workers' compensation injuries [3] - **Service Model**: Operates over 1,000 locations, including 650 brick-and-mortar facilities and over 400 on-site employer clinics [4][5] - **Patient Volume**: Facilities see about 100 patients daily, focusing on various services including drug screens, physicals, and injury care [4] - **Employer Relationships**: Over 200,000 direct employer relationships, with 98% of employers having been with Concentra for over 10 years [6][8] Financial Performance - **Revenue**: Approximately $2.2 billion with EBITDA around $425-430 million [23] - **Growth Rate**: 13% year-over-year growth in 2025; high single-digit growth excluding larger acquisitions [24] - **Cost Structure**: 71% of revenue is cost of service, with 80% being variable costs [25] - **EBITDA Margin**: Approximately 20% adjusted EBITDA margins for five consecutive years [26] - **Free Cash Flow**: Over $1 billion in free cash flow generation since 2021, with greater than 100% free cash flow conversion [27] Market Dynamics - **Workers' Compensation**: Each state sets its reimbursement rates, with expectations of a 3% increase in rates for 2026 [40][43] - **Employer Services**: Anticipated 3%-4% increase in pricing for employer services, aligning with inflationary indicators [47] - **Diversification**: No significant customer concentration risk; largest customer accounts for about 3% of revenues [14] Growth Strategy - **Acquisitions**: Over 70 acquisitions since 2016, with a focus on small M&A and de novo practices [16] - **Market Size**: The occupational health industry is valued at $176 billion, with significant growth opportunities [17] - **Demographic Trends**: An aging workforce and increasing comorbidities are expected to impact service demand positively [18] Challenges and Opportunities - **Economic Environment**: Despite economic uncertainties, Concentra has shown resilience with strong growth in work comp visit rates [37][38] - **AI Impact**: Potential job creation from AI developments, particularly in construction and data centers, may increase demand for services [19][20] Capital Allocation - **Priorities**: Focus on deleveraging, share repurchase programs, and continued M&A efforts while maintaining flexibility in capital allocation [48][49] - **Leverage Target**: Aiming for leverage below 3.0 by the end of 2026 [28][50] Future Outlook - **Investor Education**: As investors become more familiar with Concentra's business model and performance, expectations for growth in a recovering labor market are optimistic [55][56] - **Execution Confidence**: Strong historical performance and experienced leadership position the company well for future growth [56] This summary encapsulates the key points from the Concentra Group Holdings FY Conference, highlighting the company's market position, financial performance, growth strategies, and future outlook.

CytomX Therapeutics FY Conference Summary Company Overview - **Company**: CytomX Therapeutics (NasdaqGS:CTMX) - **Industry**: Oncology-focused biotechnology - **Location**: South San Francisco - **Key Personnel**: - Sean McCarthy (CEO) - Chris Ogden (CFO) - Rachel Lester (Chief Business Officer) - Wayne Chu (Chief Medical Officer) Core Points and Arguments Pipeline and Technology - CytomX has developed a unique Probody therapeutic platform aimed at masking antibodies to improve therapeutic windows in oncology [3][4] - The company is focused on two main clinical programs: - **Vasetatag masatikan (Vaseta M)**: An EpCAM-targeting Probody Topo-1 ADC for colorectal cancer [3][5] - **CX801**: A Probody version of interferon alpha-2b for melanoma [3][6] Financial Position - CytomX is well-funded, with cash reserves extending into Q2 2027, excluding potential milestones or new business developments [4] Vaseta M Program - The phase one study for Vaseta M is expanding to over 100 patients, with data updates expected by the end of Q1 2026 [8][19] - Initial data showed a 28% confirmed overall response rate and 94% disease control in late-line colorectal cancer patients [14][17] - The market for colorectal cancer is significant, with 1.9 million patients diagnosed annually, projected to exceed 3 million by 2040, and a $5 billion market opportunity in the U.S. for late-line treatment [10][22] Safety and Efficacy - Vaseta M demonstrated a favorable safety profile with no classic EpCAM toxicities, which have historically limited other EpCAM-targeting therapies [15][18] - The most common adverse event reported was grade 3 diarrhea, occurring in 21-22% of patients, which the company is actively investigating [19][36] Future Development Plans - CytomX aims to initiate a combination study of Vaseta M with bevacizumab to explore earlier lines of treatment [20][30] - The company plans to expand into other tumor types where EpCAM is expressed, potentially leading to a pan-tumor agnostic label [21][22] CX801 Program - CX801 is being developed as a novel immunotherapy for melanoma, particularly in patients who have progressed on checkpoint inhibitors [23][26] - The program aims to harness the activity of interferon alpha-2b while minimizing systemic toxicity through masking strategies [24][25] - Initial data from the combination with Keytruda is expected by the end of 2026 [30] Additional Important Content - CytomX has established partnerships with major pharmaceutical companies, including BMS, Amgen, and Moderna, enhancing its business development capabilities [4] - The company emphasizes the importance of understanding the etiology of adverse events, particularly gastrointestinal toxicities, to optimize patient management [37][38] - The strategic decision to focus on colorectal cancer was based on the abundance of the EpCAM target and the unmet medical need in this area [40][41] Conclusion CytomX Therapeutics is positioned at the forefront of innovation in oncology with its differentiated pipeline and strategic focus on unmet needs in colorectal cancer and melanoma. The upcoming data releases and ongoing studies are critical for validating the efficacy and safety of its lead programs, which could significantly impact the treatment landscape in these areas.

Summary of Prime Medicine FY Conference Call Company Overview - **Company**: Prime Medicine (NasdaqGM:PRME) - **Industry**: Biotechnology, specifically focused on gene editing technologies Core Technology - **Prime Editing**: Described as the most versatile and safest gene editing technology, capable of performing various types of edits including large deletions, insertions, and specific mutations [2][3] - **Intellectual Property**: Strong IP position with exclusive licenses from the Broad Institute, covering foundational aspects of Prime Editing [4][12] Clinical Programs - **Liver Franchise**: Focus on two main programs: - **Wilson Disease**: IND submission planned for the first half of 2026, with proof of concept data expected in 2027. Estimated patient population in the U.S. and EU is around 10,000, with potential for 25,000 patients targeted with six common mutations [5][12][13] - **Alpha-1 Antitrypsin Deficiency**: IND submission planned for mid-2026, with similar proof of concept data expected in 2027. Estimated patient population is 20,000-30,000 in the U.S. and Europe [5][14] - **Cystic Fibrosis**: Ongoing progress with plans to share proof of concept data in 2026, targeting a significant unmet need in patients who cannot tolerate current treatments [5][6] Business Development Strategy - **Collaboration with BMS**: Focus on ex vivo CAR T therapies for oncology, hematology, and immunology, with a $110 million upfront payment and significant preclinical milestones [8] - **Expansion Plans**: Emphasis on business development to broaden the reach of Prime Editing technology, including potential applications in neuro diseases and other cell therapies [20][22] Regulatory Environment - **Regulatory Changes**: Anticipated improvements in the regulatory framework that may allow for faster and cheaper movement of therapies into clinical trials [3][10] - **IND and CTA Submissions**: Clarification that both submissions are being pursued for global studies, with flexibility on which may occur first [27][28] Financial Position - **Cash Reserves**: Approximately $227 million available, with key milestones including the initiation of clinical trials for the liver franchise programs and potential arbitration resolution with Beam [47][48] Key Milestones and Future Outlook - **2026 Goals**: Focus on getting the first two in vivo programs into the clinic and achieving proof of concept data by 2027 [20][46] - **Market Potential**: High-value programs identified as those with a high probability of success and large addressable markets, particularly in orphan diseases [6][7] Risks and Challenges - **Market Competition**: Acknowledgment of competition in the gene editing space, particularly for alpha-1 antitrypsin deficiency, but confidence in Prime Editing's superior approach [39][41] - **Technological Responsibility**: Emphasis on the importance of making the right decisions to ensure the technology reaches patients effectively [42] Conclusion - **Strategic Focus**: Prime Medicine is concentrating on its liver franchise and cystic fibrosis programs, with a clear path towards clinical trials and proof of concept data, while also exploring business development opportunities to expand its technology's reach [20][46]

Summary of West Pharmaceutical Services FY Conference Call Company Overview - **Company**: West Pharmaceutical Services (NYSE: WST) - **Industry**: Injectable medicine and pharmaceutical packaging - **Revenue**: Approximately $3 billion in 2024 with a 20% operating margin [7][8] Key Points and Arguments Business Model and Growth - West is a global leader in the injectable medicine space, with a robust business model that supports long-term organic growth of 7%-9% and margin expansion [3][31] - The company has developed a significant competitive advantage through proprietary solutions, quality, reliability, and global scale [3][4] - High-value product (HVP) components represent 48% of the business and are the fastest-growing segment, expected to continue driving growth [10][26] Market Trends - The rise of biologics and biosimilars is a key growth driver, with West participating in over 90% of new biologics approvals [17][38] - Regulatory changes, particularly Annex 1 in Europe, are expected to enhance revenue through increased quality expectations and higher average selling prices (ASP) [12][22][38] - The injectable medicine market is growing rapidly, with double-digit growth anticipated for HVP components [12][40] Product Portfolio - West produces over 41 billion components annually, with a focus on high-value products such as elastomer components and drug delivery devices [4][5] - The company serves a diverse customer base, including the top 30 pharmaceutical companies, and its elastomer components are used in approximately 75% of injectable drugs on the market [6][9] Financial Performance - HVP components grew 13.3% on an organic basis in Q3 2025, driven by GLP-1s and new biologics launches [40] - The company expects continued growth in HVP components, although at a slower pace than the recent 50% increase in GLP-1s [41][43] - Free cash flow grew around 54% in the first nine months of the previous year, indicating strong cash generation capabilities [32] Strategic Initiatives - West has made significant investments in proprietary products and contract manufacturing, particularly during the COVID-19 pandemic [23] - The company is transitioning to a more focused operating unit structure to enhance accountability and speed in responding to customer needs [27][28] - A recent decision to sell the SmartDose business was made to redirect resources towards higher growth opportunities, indicating a strategic shift [48][49] Management and Team - The management team has been strengthened with new additions, enhancing the company's ability to innovate and respond to market demands [27][29] - The transition to an operating unit structure aims to drive more accountability and speed in decision-making [28] Additional Important Information - The company is well-positioned to support onshoring trends in the U.S. and is leveraging existing assets to meet growing demand [13][39] - The focus on high-value products is expected to continue driving margin expansion and overall business growth [31][33] - West's strong balance sheet and cash generation allow for disciplined capital allocation towards organic growth and shareholder returns [32][54]

Summary of Intellia Therapeutics FY Conference Call Company Overview - **Company**: Intellia Therapeutics (NasdaqGM: NTLA) - **Industry**: Biotechnology, specifically focused on CRISPR medicine and genetic diseases - **Key Products**: Lombozi (for hereditary angioedema) and Nexi (for transthyretin amyloidosis) Core Points and Arguments Leadership in CRISPR Medicine - Intellia has been a leader in CRISPR medicine since 2014, focusing on in vivo treatment of genetic diseases [2][3] - The company is nearing completion of trials that may lead to the first approved CRISPR therapeutics [2] Clinical Trials and Pipeline - Three phase three trials are ongoing, with over 600 patients dosed [2][3] - Lombozi is positioned as the first product to potentially offer patients freedom from attacks and additional therapy for hereditary angioedema [4][5] - Nexi aims to reset the treatment paradigm for transthyretin amyloidosis, with potential to stabilize and reverse the disease [5][6] Market Potential - The hereditary angioedema market is currently valued at over $3 billion and is expected to double by the end of the decade [5][10] - The TTR amyloidosis market is projected to exceed $16 billion by the end of the decade [22] Patient Outcomes and Demand - 80% of patients on current therapies still experience attacks, indicating a significant unmet need [10][11] - In contrast, 76% of patients in Intellia's trials remained attack-free and long-term prophylaxis-free after treatment [11] - High patient interest in Lombozi, with 99% expressing willingness to take the drug if offered [15][16] Safety and Efficacy - The safety profile of Lombozi shows minimal adverse effects, primarily infusion reactions [14] - Nexi demonstrated a 70% reduction in mortality in a matched cohort study, indicating strong efficacy [25][26] Regulatory and Clinical Hold - Nexi is currently under clinical hold due to a patient incident, but the company is actively engaged with the FDA to resolve this [27][43] - Historical timelines for clinical holds suggest a resolution could take three to nine months [44] Commercialization Strategy - Intellia is preparing for a commercial launch of Lombozi in the first half of 2027, with a focus on building relationships with payers and key opinion leaders [20][37] - The company is also considering international commercialization and potential partnerships for broader market access [46][47] Future Milestones - Anticipated milestones include presenting top-line data for Lombozi by mid-2026 and submitting a Biologics License Application (BLA) in the second half of the year [7][40] Additional Important Content - The company emphasizes the need for disruptive innovation in the hereditary angioedema market, highlighting the limitations of current therapies [10][34] - Physicians surveyed indicated a strong willingness to prescribe Lombozi, with 92% identifying patients who would benefit from the drug [17] - The company is confident in its ability to resume enrollment and complete trials post-clinical hold, given the high interest from both patients and investigators [51][52]

Intuitive Surgical (NasdaqGS:ISRG) FY Conference January 14, 2026 12:00 PM ET Company ParticipantsDavid Rosa - CEO and Member of Board of DirectorsJamie Samath - EVP and CFOConference Call ParticipantsRobbie Marcus - Senior AnalystRobbie MarcusGood morning, everyone. I'm Robbie Marcus, the MedTech analyst at JPMorgan. Very happy to host our next session with Intuitive Surgical. CEO Dave Rosa will give a presentation, and we'll be joined on stage by some Q&A. Dave?Jamie SamathActually, no.David RosaAll right ...